Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
News
-
July 4, 2022Targovax: Completion of drop-down demerger
-
June 23, 2022Targovax announces that the FDA has granted authorization to initiate clinical trials with the enhanced TG01 RAS vaccine in the USA
-
June 23, 2022Targovax: FDA gir tillatelse til å starte kliniske studier med ny og forbedret TG01 kreftvaksine i USA
-
June 7, 2022Targovax ASA: Registration of share capital increase following settlement of restricted stock units and exercise of employee options
Q1 First Quarter 2022
Targovax ASA (OSE: TRVX) published its first quarter 2022 results on Thursday 12 May 2022.